# Anticoagulation in Post MI LV Thrombus Trial in Nepal

Study · id `cardio:ct-nct05794399` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05794399](<https://clinicaltrials.gov/study/NCT05794399>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05794399

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 196 participants.

## Technical summary

Registry record NCT05794399. Randomized; single masking; primary purpose treatment. Start 2023-06-19 (actual); primary completion 2028-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 196 participants (planned count; ClinicalTrials.gov record NCT05794399, source copy `cardio:ctgov-nct05794399-2026-11-18`, retrieved 2026-11-18)
- Started: 2023-06-19 (actual) (ClinicalTrials.gov record NCT05794399, source copy `cardio:ctgov-nct05794399-2026-11-18`, retrieved 2026-11-18)
- Primary completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT05794399, source copy `cardio:ctgov-nct05794399-2026-11-18`, retrieved 2026-11-18)
- Completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT05794399, source copy `cardio:ctgov-nct05794399-2026-11-18`, retrieved 2026-11-18)
- Countries: Nepal (ClinicalTrials.gov record NCT05794399, source copy `cardio:ctgov-nct05794399-2026-11-18`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05794399-2026-11-18`, retrieved 2026-11-18)

## The registry's words

- Brief title: Anticoagulation in Post MI LV Thrombus Trial in Nepal
- Acronym: WaRMIN
- Condition: Left Ventricular Thrombus
- Condition: Myocardial Infarction
- Intervention (Drug): Rivaroxaban
- Intervention (Drug): Warfarin
- Lead sponsor: Shahid Gangalal National Heart Centre
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)

## Provenance

Content hash: 2d9aae3a748c5b076a3f1b8a401c45ce00fd084539721c7c4db8034d1d95e3e4
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
